Tolmar Patent-Cliff Exposure & CMS Drug Spending Portfolio

Tolmar (US): 7 reconciled FDA prescription therapies, $61.0M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$61.0M
2024 Medicare Part D Spend$20.1M
2024 Medicaid Spend$40.8M
California HCAI SB 17 Filings3 WAC filings (max 19.9% 2-yr change)